BTBD9 rs16826005: What Your Genotype Means
The rs16826005 variant is a non-coding genetic marker located within the BTBD9 gene. It is widely recognized in scientific literature for its statistical association with an increased risk of restless legs syndrome (RLS) and periodic limb movements during sleep.
What each genotype means
Lower risk profile
This genotype is associated with a lower statistical risk for restless legs syndrome and periodic limb movements during sleep compared to those carrying the T allele. While this suggests a reduced genetic predisposition, it does not guarantee the absence of these conditions, as sleep health is influenced by many genetic and environmental factors.
Carried by approximately 52% of individuals of European ancestry, assuming a minor allele frequency of 0.28.
Increased risk profile
Carrying one copy of the T allele is associated with an increased statistical risk for developing restless legs syndrome and periodic limb movements during sleep. Research indicates that variants in the BTBD9 gene play a role in sleep regulation and motor control, though this association is considered a susceptibility factor rather than a direct cause.
Carried by approximately 40% of individuals of European ancestry, assuming a minor allele frequency of 0.28.
Higher risk profile
This genotype is associated with the highest statistical risk for restless legs syndrome and periodic limb movements during sleep among the common variants of this gene. Because this is a susceptibility marker, it is important to remember that many people with this genotype will not develop these conditions, and you should consult a healthcare professional if you experience symptoms like sleep disruption or an urge to move your legs.
Carried by approximately 8% of individuals of European ancestry, assuming a minor allele frequency of 0.28.
Understanding the rs16826005 Variant
The rs16826005 variant is a single nucleotide polymorphism (SNP) situated within the BTBD9 gene on human chromosome 6. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. Because rs16826005 is located in a non-coding region of the gene, it does not directly alter the sequence of the protein produced by BTBD9. Instead, researchers study such variants to understand how they might influence gene expression or regulation. This specific variant has been identified through genome-wide association studies (GWAS) as a significant marker for sleep-related movement disorders. It is important to note that while the variant is statistically linked to these conditions, it is not a direct cause, and many individuals who carry the variant do not experience symptoms of restless legs syndrome.
The Role of the BTBD9 Gene
The BTBD9 gene encodes a protein containing a BTB/POZ domain, a structural motif known to facilitate protein-protein interactions. While the exact biological mechanisms are still being investigated, research using animal models, such as mice and fruit flies, suggests that BTBD9 plays a role in neurological function, including the regulation of sleep-wake cycles and synaptic transmission. Studies have shown that the loss or alteration of BTBD9 function can influence the activity of neurons in the striatum and cerebellum, areas of the brain involved in motor control. By modulating these pathways, the gene may influence the sensory and motor restlessness characteristic of restless legs syndrome. Ongoing research continues to bridge the gap between these molecular functions and the clinical presentation of sleep disorders in humans.
Research and Evidence Strength
The association between BTBD9 variants and restless legs syndrome (RLS) is supported by multiple large-scale genome-wide association studies. Researchers have consistently observed that specific alleles at the rs16826005 locus appear more frequently in individuals diagnosed with RLS compared to the general population. Despite these robust statistical findings, the evidence is categorized as having limited clinical utility for individual diagnosis. This is because the genetic architecture of RLS is complex, involving many different genes and environmental factors. Furthermore, the effect size of any single variant like rs16826005 is relatively small. Consequently, while the association is scientifically significant, it cannot be used to predict whether an individual will develop the condition. The research community views this variant as one piece of a much larger, multifactorial puzzle regarding sleep health.
Population Frequency
The rs16826005 variant is relatively common, with a minor allele frequency (MAF) of approximately 0.28 in populations of European ancestry. This means that a significant portion of the population carries at least one copy of the risk-associated allele. Because the variant is common, it is considered a susceptibility factor rather than a rare mutation that guarantees a specific health outcome. Frequency can vary across different global populations, and researchers often emphasize the importance of studying diverse cohorts to understand how genetic risk factors manifest across different ancestral backgrounds. The prevalence of this variant highlights that genetic predisposition is a widespread phenomenon, yet the actual manifestation of symptoms remains highly variable among individuals.
Interpreting Your Genetic Information
If you have received information about your rs16826005 genotype, it is important to view it in the context of your overall health. This variant is a marker of statistical risk, not a diagnostic tool. Having a genotype associated with higher risk does not mean you will develop restless legs syndrome, and conversely, not having it does not guarantee you will not. If you are experiencing symptoms such as an irresistible urge to move your legs, particularly at night, or if you suffer from chronic sleep disruption, you should consult a healthcare professional. They can evaluate your symptoms, medical history, and lifestyle factors to provide appropriate guidance. Never use genetic data to self-diagnose or alter medical treatments without professional supervision. Your clinician is the best resource for interpreting how this information relates to your personal health journey.
How common is this variant?
The rs16826005 variant is common, with a minor allele frequency of approximately 0.28 in European populations.
Frequently asked questions
Does having the rs16826005 variant mean I have restless legs syndrome?
No. This variant is a statistical risk factor, not a diagnostic test. Many people with this variant never develop restless legs syndrome, and the condition is influenced by many other genetic and environmental factors.
Can I use this genetic information to prevent sleep disorders?
There is no evidence that knowing your genotype for this variant allows for specific prevention strategies. If you are concerned about your sleep quality, focus on healthy sleep hygiene and consult a doctor for personalized advice.
Is the BTBD9 gene only related to sleep?
While BTBD9 is primarily studied in the context of sleep-related movement disorders, some research has explored its potential links to other neurological conditions like Tourette syndrome. However, these associations are less established than those for restless legs syndrome.
Should I share my rs16826005 results with my doctor?
You can share any health information with your doctor, but they may not find this specific SNP result clinically actionable. Focus your conversation on any symptoms you are experiencing rather than the genetic result itself.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16826005?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BTBD9
This variant in the BTBD9 gene is associated with susceptibility to restless legs syndrome, a condition that can significantly impact sleep quality during pregnancy.
The minor allele of this SNP is associated with a reduced risk of developing restless legs syndrome.
Intronic variant strongly associated with restless legs syndrome (RLS) susceptibility and periodic limb movements during sleep (PLMS), mediating altered iron homeostasis.
Genome-wide significant intronic susceptibility variant in BTBD9 strongly predisposing individuals to restless legs syndrome and periodic limb movements in sleep.
A regulatory intron variant in BTBD9 strongly associated with periodic limb movements in sleep and fragmented sleep architecture.
Well-validated intronic risk variant in BTBD9 strongly associated with periodic limb movement in sleep (PLMS) and restless legs syndrome (RLS).